Artivion, Inc. (AORT) Earnings Call Analysis
NYSE · Healthcare · Medical Devices
Next earnings call: 2026-08-06
(Q2 2026)
— full calendar
Earnings Reports
-
Artivion (AORT) Q4 2025: Stent Graft Revenue Jumps 36%, Propelling Double-Digit Growth Outlook
June 16, 2026
-
Artivion (AORT) Q1 2026: EBITDA Margin Expands 130bps as Aortic Arch Portfolio Strategy Advances
May 08, 2026
-
Artivion (AORT) Q3 2025: Stent Graft Revenue Surges 31%, Unlocking High-Margin U.S. Growth
November 07, 2025
-
Artivion (AORT) Q2 2025: ONIX Valve Grows 24%, Driving Margin Expansion and Pipeline Momentum
August 08, 2025
-
Artivion (AORT) Q1 2025: Stent Graft Revenue Jumps 19% as AMDS and Onyx Recovery Fuel Guidance Raise
July 06, 2025
-
Artivion (AORT) Q3 2024: EBITDA Margin Expands 270bps as Global Portfolio Drives Double-Digit Growth
November 07, 2024
-
Artivion (AORT) Q2 2024: EBITDA Margin Expands 350bps as On-X and Stent Grafts Drive Double-Digit Growth
August 08, 2024
-
Artivion (AORT) Q1 2024: EBITDA Margin Expands 480bps as Proprietary Portfolio Drives Global Growth
May 06, 2024
-
Artivion (AORT) Q4 2023: 72% Mortality Reduction in AMDS Trial Sets Stage for U.S. Market Entry
February 15, 2024